SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Identifying patients with chest pain that is of cardiac origin is crucial owing to the high mortality and morbidity of cardiovascular diseases. History, electrocardiogram, and cardiac biomarkers are ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

Patients with takotsubo syndrome have increased risk for rehospitalization compared with the general population, according to ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

Innodata sees explosive growth with LLM training data demand. See why INOD stock’s future depends on automation and continued ...

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A decade after the first introduction of angiography-derived fractional flow reserve (FFR), we are now entering an era in which simplified image-derived solutions could replace invasive assessment ...